Allergan plc / Topokine Therapeutics, Inc.

Steatoblepharon (Under-Eye Bags) / Non-Invasive Fat Reduction

Disease Overview

Steatoblepharon is the protrusion of orbital fat through the lower eyelid, producing the visible 'under-eye bags' that age the periorbital area. It affects an estimated 40 million Americans and traditionally requires surgical lower-lid blepharoplasty — an invasive, costly procedure with downtime — leaving a meaningful gap for non-invasive medical alternatives.

Competitive Landscape

At the time of Allergan's April 2016 Topokine acquisition, no FDA-approved topical or pharmacologic therapy existed for steatoblepharon — the entire ~40M-American addressable population defaulted to surgical lower blepharoplasty (oculoplastic/cosmetic surgeons) or off-label dermal filler camouflage with hyaluronic acid (Allergan's own Juvederm Volbella, Restylane, Belotero). The closest pharmacologic precedent was Kybella (deoxycholic acid injection from Kythera, acquired by Allergan in 2015 for $2.1B) — but Kybella was approved only for submental fat (double chin), not periorbital, and required injection. Topokine's XAF5 (a topical small-molecule prostaglandin analog applied nightly to the lower eyelid) was first-in-class: penetrating skin and acting pharmacologically on adipocytes to shrink fat. XAF5 had met its Phase 2 primary endpoint (XOPH5-OINT-2) and entered the pivotal XOPH5-OINT-3 Phase 2b/3 in January 2016. For Allergan, the deal extended its medical aesthetics leadership beyond Botox, fillers, and Kybella into a third 'non-invasive aesthetic' modality — topical pharmacology — alongside ~70 mid-to-late stage programs. Dermatologist Jeffrey Dover characterized topical fat reduction as 'an important step forward'. XAF5 was ultimately discontinued post-deal after later trial readouts disappointed, but at announcement the asset was viewed as a category-creator.